BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Guo W, Wang J, Wei H. Serum YKL-40 Level Positively Correlates With Uterine Leiomyomas. Reprod Sci 2016;23:1559-64. [DOI: 10.1177/1933719116648219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
3 Ueland T, Laugsand LE, Vatten LJ, Janszky I, Platou C, Michelsen AE, Damås JK, Aukrust P, Åsvold BO. Extracellular matrix markers and risk of myocardial infarction: The HUNT Study in Norway. Eur J Prev Cardiol 2017;24:1161-7. [PMID: 28429960 DOI: 10.1177/2047487317703826] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Laucyte-Cibulskiene A, Ward LJ, Ebert T, Tosti G, Tucci C, Hernandez L, Kautzky-Willer A, Herrero MT, Norris CM, Pilote L, Söderberg M, Brismar TB, Ripsweden J, Stenvinkel P, Raparelli V, Kublickiene K; GOING-FWD Consortium. Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality. Biol Sex Differ 2021;12:50. [PMID: 34526107 DOI: 10.1186/s13293-021-00393-0] [Reference Citation Analysis]
5 Lekva T, Sugulle M, Moe K, Redman C, Dechend R, Staff AC. Multiplex Analysis of Circulating Maternal Cardiovascular Biomarkers Comparing Preeclampsia Subtypes. Hypertension 2020;75:1513-22. [PMID: 32336238 DOI: 10.1161/HYPERTENSIONAHA.119.14580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
6 Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, Gøtze JP, Johansen JS, Kastrup J. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scandinavian Journal of Clinical and Laboratory Investigation 2011;71:439-47. [DOI: 10.3109/00365513.2011.586470] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
7 Parisi GF, Papale M, Tardino L, Nenna R, Midulla F, Leonardi S. Biomarkers in Pediatric Lung Diseases Including Cystic Fibrosis. CRMR 2020;15:163-73. [DOI: 10.2174/1573398x15666190521112824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Harutyunyan M, Gøtze JP, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjøller E, Kolmos HJ, Gluud C, Kastrup J. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology 2013;218:945-51. [PMID: 23294528 DOI: 10.1016/j.imbio.2012.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
9 Fantino E, Gangell CL, Hartl D, Sly PD; AREST CF. Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease. BMC Pulm Med 2014;14:28. [PMID: 24576297 DOI: 10.1186/1471-2466-14-28] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
10 Leonardi S, Parisi GF, Capizzi A, Manti S, Cuppari C, Scuderi MG, Rotolo N, Lanzafame A, Musumeci M, Salpietro C. YKL-40 as marker of severe lung disease in cystic fibrosis patients. Journal of Cystic Fibrosis 2016;15:583-6. [DOI: 10.1016/j.jcf.2015.12.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
11 Harutyunyan M, Johansen JS, Mygind ND, Reuter SB, Kastrup J. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomark Med 2014;8:977-87. [PMID: 25343670 DOI: 10.2217/bmm.14.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, Gøtze JP, Johansen JS, Kastrup J; The CLARICOR Trial Group. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2011;60:281-7. [DOI: 10.1007/s00011-010-0266-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
13 Asghar O, Alam U, Hayat SA, Aghamohammadzadeh R, Heagerty AM, Malik RA. Diabetes, Obesity and Atrial Fibrillation: Epidemiology, Mechanisms and Interventions. J Atr Fibrillation 2013;6:869. [PMID: 28496876 DOI: 10.4022/jafib.869] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Bouwens E, van den Berg VJ, Akkerhuis KM, Baart SJ, Caliskan K, Brugts JJ, Mouthaan H, Ramshorst JV, Germans T, Umans VAWM, Boersma E, Kardys I. Circulating Biomarkers of Cell Adhesion Predict Clinical Outcome in Patients with Chronic Heart Failure. J Clin Med 2020;9:E195. [PMID: 31936828 DOI: 10.3390/jcm9010195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Asghar O, Alam U, Hayat SA, Aghamohammadzadeh R, Heagerty AM, Malik RA. Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Curr Cardiol Rev 2012;8:253-64. [PMID: 22920475 DOI: 10.2174/157340312803760749] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
16 Gao M, Wei Y, Xu Q, Ji R, Han Z, Jiang T. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. Ann Clin Biochem 2019;56:95-9. [DOI: 10.1177/0004563218786979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 2012;217:652-6. [PMID: 22209156 DOI: 10.1016/j.imbio.2011.11.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]